| Non-adjusted model | Adjusted model | ||
---|---|---|---|---|
 | SHR (95% CI) | p value | SHR (95% CI) | p value |
Whole population (N=1593) | Â | Â | Â | Â |
Continuous per 1 unit increase | 1.14 (1.08-1.21) | <0.001 | 1.10 (1.03-1.17) | 0.006 |
Tertile 1 (<5.5Â mg/dL) | Reference | -- | Reference | -- |
Tertile 2 (5.5-7.0Â mg/dL) | 0.94 (0.82-1.08) | 0.370 | 0.94 (0.82-1.08) | 0.410 |
Tertile 3 (>7.0Â mg/dL) | 1.12 (1.03-1.21) | 0.007 | 1.06 (0.97-1.17) | 0.200 |
Men (N=897, 56.3%) | Â | Â | Â | Â |
Continuous per 1 unit increase | 1.17 (1.09-1.26) | <0.001 | 1.17 (1.08-1.27) | <0.001 |
Tertile 1 (<5.9Â mg/dL) | Reference | -- | Reference | -- |
Tertile 2 (5.9-7.4Â mg/dL) | 0.97 (0.81-1.16) | 0.740 | 1.01 (0.84-1.22) | 0.900 |
Tertile 3 (>7.4Â mg/dL) | 1.21 (1.09-1.35) | <0.001 | 1.19 (1.05-1.35) | 0.006 |
Women (N=696, 43.7%) | Â | Â | Â | Â |
Continuous per 1 unit increase | 1.10 (1.00-1.20) | 0.044 | 0.98 (0.87-1.10) | 0.690 |
Tertile 1 (<5.1Â mg/dL) | Reference | -- | Reference | -- |
Tertile 2 (5.1-6.5Â mg/dL) | 1.05 (0.87-1.28) | 0.590 | 0.93 (0.75-1.14) | 0.460 |
Tertile 3 (>6.5Â mg/dL) | 1.08 (0.95-1.22) | 0.260 | 0.90 (0.77-1.06) | 0.200 |